BioNTech SE (BNTX)
NASDAQ: BNTX · Real-Time Price · USD
110.03
+2.69 (2.51%)
At close: Aug 4, 2025, 4:00 PM
111.86
+1.83 (1.66%)
Pre-market: Aug 5, 2025, 5:43 AM EDT
Marinus Pharmaceuticals Stock Forecast
Stock Price Forecast
The 18 analysts that cover Marinus Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $140.27, which forecasts a 27.48% increase in the stock price over the next year. The lowest target is $110 and the highest is $171.44.
Price Target: $140.27 (+27.48%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Marinus Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 10 | 10 | 10 | 10 | 10 | 10 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 3 | 3 | 4 | 4 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 17 | 17 | 18 | 18 | 18 | 18 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| B of A Securities | B of A Securities | Strong Buy Maintains $127 → $126 | Strong Buy | Maintains | $127 → $126 | +14.51% | Jul 16, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $132 → $133 | Buy | Maintains | $132 → $133 | +20.88% | Jul 10, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $138 | Strong Buy | Reiterates | $138 | +25.42% | Jun 25, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $145 → $138 | Strong Buy | Maintains | $145 → $138 | +25.42% | Jun 16, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $134 → $145 | Strong Buy | Maintains | $134 → $145 | +31.78% | Jun 5, 2025 |
Financial Forecast
Revenue This Year
2.01B
from 2.75B
Decreased by -26.79%
Revenue Next Year
2.26B
from 2.01B
Increased by 12.31%
EPS This Year
-5.30
from -2.77
EPS Next Year
-4.72
from -5.30
Financial currency is EUR. Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 2.4B | 3.7B | 3.3B | ||
| Avg | 2.0B | 2.3B | 2.3B | ||
| Low | 1.7B | 1.5B | 1.5B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -11.3% | 84.7% | 45.0% | ||
| Avg | -26.8% | 12.3% | 2.8% | ||
| Low | -39.4% | -26.9% | -33.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.24 | -0.67 | -1.05 | ||
| Avg | -5.30 | -4.72 | -5.22 | ||
| Low | -7.71 | -8.58 | -9.34 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.